- Home
- NBY vs ATXI Comparison
NBY vs ATXI Comparison
Compare NBY & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- ATXI
- Stock Information
- Founded
- NBY 2000
- ATXI 2015
- Country
- NBY United States
- ATXI United States
- Employees
- NBY N/A
- ATXI N/A
- Industry
- NBY
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- ATXI Health Care
- Exchange
- NBY Nasdaq
- ATXI Nasdaq
- Market Cap
- NBY 2.8M
- ATXI 3.0M
- IPO Year
- NBY 2007
- ATXI 2017
- Fundamental
- Price
- NBY $0.73
- ATXI $1.85
- Analyst Decision
- NBY Strong Buy
- ATXI
- Analyst Count
- NBY 1
- ATXI 0
- Target Price
- NBY $0.85
- ATXI N/A
- AVG Volume (30 Days)
- NBY 492.7K
- ATXI 61.4K
- Earning Date
- NBY 11-07-2024
- ATXI 11-14-2024
- Dividend Yield
- NBY N/A
- ATXI N/A
- EPS Growth
- NBY N/A
- ATXI N/A
- EPS
- NBY N/A
- ATXI N/A
- Revenue
- NBY $13,844,000.00
- ATXI N/A
- Revenue This Year
- NBY N/A
- ATXI N/A
- Revenue Next Year
- NBY $17.31
- ATXI N/A
- P/E Ratio
- NBY N/A
- ATXI N/A
- Revenue Growth
- NBY 15.40
- ATXI N/A
- 52 Week Low
- NBY $0.07
- ATXI $1.60
- 52 Week High
- NBY $6.30
- ATXI $15.00
- Technical
- Relative Strength Index (RSI)
- NBY 63.10
- ATXI 47.67
- Support Level
- NBY $0.65
- ATXI $1.72
- Resistance Level
- NBY $0.78
- ATXI $2.04
- Average True Range (ATR)
- NBY 0.06
- ATXI 0.19
- MACD
- NBY 0.01
- ATXI -0.00
- Stochastic Oscillator
- NBY 83.07
- ATXI 33.39
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.